Selected research
Industry Research
Gene Cell Therapy CDMO Industry Research Report 2026
Market perspective
The global Gene Cell Therapy CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Gene Cell Therapy CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Gene Cell Therapy CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Gene Cell Therapy CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Gene Cell Therapy CDMO include Catalent, Lonza, Charles River, Oxford Biomedica, Novartis, OBiO, GenScript, Pharmaron and Porton, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Gene Cell Therapy CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Gene Cell Therapy CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gene Cell Therapy CDMO Market by Company
Catalent
Lonza
Charles River
Oxford Biomedica
Novartis
OBiO
GenScript
Pharmaron
Porton
Resilience
SK Pharmteco
Forge Biologics
Andelyn Biosciences
Roslin CT
eXmoor Pharma
Advanced Therapies
Catalent Biologics
Patheon Pharma Services
Gene Cell Therapy CDMO Segment by Type
Immune Cells
Stem Cell
Viral Vector
Plasmid DNA
Gene Cell Therapy CDMO Segment by Application
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Hospital
Others
Gene Cell Therapy CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Cell Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gene Cell Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Cell Therapy CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Gene Cell Therapy CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immune Cells
- Stem Cell
- Viral Vector
- Plasmid DNA
Applications
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutions
- Hospital
- Others
Companies covered
- Catalent
- Lonza
- Charles River
- Oxford Biomedica
- Novartis
- OBiO
- GenScript
- Pharmaron
- Porton
- Resilience
- SK Pharmteco
- Forge Biologics
- Andelyn Biosciences
- Roslin CT
- eXmoor Pharma
- Advanced Therapies
- Catalent Biologics
- Patheon Pharma Services
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Gene Cell Therapy CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Immune Cells
- 2.2.3 Stem Cell
- 2.2.4 Viral Vector
- 2.2.5 Plasmid DNA
- 2.3 Gene Cell Therapy CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical and Biotechnology Companies
- 2.3.3 Research and Academic Institutions
- 2.3.4 Hospital
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Gene Cell Therapy CDMO Breakdown Data by Type
- 3.1 Global Gene Cell Therapy CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Gene Cell Therapy CDMO Forecasted Market Size by Type (2027-2032)
4 Gene Cell Therapy CDMO Breakdown Data by Application
- 4.1 Global Gene Cell Therapy CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Gene Cell Therapy CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Gene Cell Therapy CDMO Market Perspective (2021-2032)
- 5.2 Global Gene Cell Therapy CDMO Growth Trends by Region
- 5.2.1 Global Gene Cell Therapy CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Gene Cell Therapy CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Gene Cell Therapy CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Gene Cell Therapy CDMO Market Dynamics
- 5.3.1 Gene Cell Therapy CDMO Industry Trends
- 5.3.2 Gene Cell Therapy CDMO Market Drivers
- 5.3.3 Gene Cell Therapy CDMO Market Challenges
- 5.3.4 Gene Cell Therapy CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Gene Cell Therapy CDMO Players by Revenue
- 6.1.1 Global Top Gene Cell Therapy CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Gene Cell Therapy CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Gene Cell Therapy CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Gene Cell Therapy CDMO Head Office and Area Served
- 6.4 Global Gene Cell Therapy CDMO Players, Product Type & Application
- 6.5 Global Gene Cell Therapy CDMO Manufacturers Established Date
- 6.6 Global Gene Cell Therapy CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Gene Cell Therapy CDMO Market Size (2021-2032)
- 7.2 North America Gene Cell Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Gene Cell Therapy CDMO Market Size by Country (2021-2026)
- 7.4 North America Gene Cell Therapy CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Gene Cell Therapy CDMO Market Size (2021-2032)
- 8.2 Europe Gene Cell Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Gene Cell Therapy CDMO Market Size by Country (2021-2026)
- 8.4 Europe Gene Cell Therapy CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Gene Cell Therapy CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Gene Cell Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Gene Cell Therapy CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Gene Cell Therapy CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Gene Cell Therapy CDMO Market Size (2021-2032)
- 10.2 South America Gene Cell Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Gene Cell Therapy CDMO Market Size by Country (2021-2026)
- 10.4 South America Gene Cell Therapy CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Gene Cell Therapy CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Gene Cell Therapy CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Catalent
- 12.1.1 Catalent Company Information
- 12.1.2 Catalent Business Overview
- 12.1.3 Catalent Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.1.4 Catalent Gene Cell Therapy CDMO Product Portfolio
- 12.1.5 Catalent Recent Developments
- 12.2 Lonza
- 12.2.1 Lonza Company Information
- 12.2.2 Lonza Business Overview
- 12.2.3 Lonza Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.2.4 Lonza Gene Cell Therapy CDMO Product Portfolio
- 12.2.5 Lonza Recent Developments
- 12.3 Charles River
- 12.3.1 Charles River Company Information
- 12.3.2 Charles River Business Overview
- 12.3.3 Charles River Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.3.4 Charles River Gene Cell Therapy CDMO Product Portfolio
- 12.3.5 Charles River Recent Developments
- 12.4 Oxford Biomedica
- 12.4.1 Oxford Biomedica Company Information
- 12.4.2 Oxford Biomedica Business Overview
- 12.4.3 Oxford Biomedica Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.4.4 Oxford Biomedica Gene Cell Therapy CDMO Product Portfolio
- 12.4.5 Oxford Biomedica Recent Developments
- 12.5 Novartis
- 12.5.1 Novartis Company Information
- 12.5.2 Novartis Business Overview
- 12.5.3 Novartis Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.5.4 Novartis Gene Cell Therapy CDMO Product Portfolio
- 12.5.5 Novartis Recent Developments
- 12.6 OBiO
- 12.6.1 OBiO Company Information
- 12.6.2 OBiO Business Overview
- 12.6.3 OBiO Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.6.4 OBiO Gene Cell Therapy CDMO Product Portfolio
- 12.6.5 OBiO Recent Developments
- 12.7 GenScript
- 12.7.1 GenScript Company Information
- 12.7.2 GenScript Business Overview
- 12.7.3 GenScript Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.7.4 GenScript Gene Cell Therapy CDMO Product Portfolio
- 12.7.5 GenScript Recent Developments
- 12.8 Pharmaron
- 12.8.1 Pharmaron Company Information
- 12.8.2 Pharmaron Business Overview
- 12.8.3 Pharmaron Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.8.4 Pharmaron Gene Cell Therapy CDMO Product Portfolio
- 12.8.5 Pharmaron Recent Developments
- 12.9 Porton
- 12.9.1 Porton Company Information
- 12.9.2 Porton Business Overview
- 12.9.3 Porton Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.9.4 Porton Gene Cell Therapy CDMO Product Portfolio
- 12.9.5 Porton Recent Developments
- 12.10 Resilience
- 12.10.1 Resilience Company Information
- 12.10.2 Resilience Business Overview
- 12.10.3 Resilience Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.10.4 Resilience Gene Cell Therapy CDMO Product Portfolio
- 12.10.5 Resilience Recent Developments
- 12.11 SK Pharmteco
- 12.11.1 SK Pharmteco Company Information
- 12.11.2 SK Pharmteco Business Overview
- 12.11.3 SK Pharmteco Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.11.4 SK Pharmteco Gene Cell Therapy CDMO Product Portfolio
- 12.11.5 SK Pharmteco Recent Developments
- 12.12 Forge Biologics
- 12.12.1 Forge Biologics Company Information
- 12.12.2 Forge Biologics Business Overview
- 12.12.3 Forge Biologics Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.12.4 Forge Biologics Gene Cell Therapy CDMO Product Portfolio
- 12.12.5 Forge Biologics Recent Developments
- 12.13 Andelyn Biosciences
- 12.13.1 Andelyn Biosciences Company Information
- 12.13.2 Andelyn Biosciences Business Overview
- 12.13.3 Andelyn Biosciences Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.13.4 Andelyn Biosciences Gene Cell Therapy CDMO Product Portfolio
- 12.13.5 Andelyn Biosciences Recent Developments
- 12.14 Roslin CT
- 12.14.1 Roslin CT Company Information
- 12.14.2 Roslin CT Business Overview
- 12.14.3 Roslin CT Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.14.4 Roslin CT Gene Cell Therapy CDMO Product Portfolio
- 12.14.5 Roslin CT Recent Developments
- 12.15 eXmoor Pharma
- 12.15.1 eXmoor Pharma Company Information
- 12.15.2 eXmoor Pharma Business Overview
- 12.15.3 eXmoor Pharma Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.15.4 eXmoor Pharma Gene Cell Therapy CDMO Product Portfolio
- 12.15.5 eXmoor Pharma Recent Developments
- 12.16 Advanced Therapies
- 12.16.1 Advanced Therapies Company Information
- 12.16.2 Advanced Therapies Business Overview
- 12.16.3 Advanced Therapies Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.16.4 Advanced Therapies Gene Cell Therapy CDMO Product Portfolio
- 12.16.5 Advanced Therapies Recent Developments
- 12.17 Catalent Biologics
- 12.17.1 Catalent Biologics Company Information
- 12.17.2 Catalent Biologics Business Overview
- 12.17.3 Catalent Biologics Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.17.4 Catalent Biologics Gene Cell Therapy CDMO Product Portfolio
- 12.17.5 Catalent Biologics Recent Developments
- 12.18 Patheon Pharma Services
- 12.18.1 Patheon Pharma Services Company Information
- 12.18.2 Patheon Pharma Services Business Overview
- 12.18.3 Patheon Pharma Services Revenue in Gene Cell Therapy CDMO Business (2021-2026)
- 12.18.4 Patheon Pharma Services Gene Cell Therapy CDMO Product Portfolio
- 12.18.5 Patheon Pharma Services Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst